The LLS Blog
Read about survivors, research, fundraising and advocacy.
Immunotherapies on a Roll at #ASH20
More than three years after the first chimeric antigen receptor (CAR) T-cell therapy achieved U.S. Food and Drug Administration (FDA) approval, the revolutionary approach that has upended blood cancer treatment continues to generate excitement.
Two Prominent Themes of 2020 Make an Appearance at #ASH20: Covid-19 and Racial Disparities
With the COVID-19 pandemic driving yet another science conference to the virtual world, it is fitting that the 62nd ASH Annual Meeting and Exposition officially kicked off today with a virtual fireside chat via live stream featuring none other than Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, and a member of the administration’s coronavirus task force.
LLS ANSWERS 10 QUESTIONS ABOUT COVID-19 VACCINES
Here at The Leukemia & Lymphoma Society (LLS), we hear from blood cancer patients and caregivers each day about the profound effects of the COVID-19 pandemic on their cancer care, treatment, and daily lives.
LLS’s Therapy Acceleration Program Accelerates Progress for Patients
In 2007, when I served as The Leukemia & Lymphoma Society’s Chief Scientific Officer, I conceived and launched the LLS venture philanthropy initiative, the Therapy Acceleration Program (TAP). Our goal was to expand beyond traditional research grants and to bring much-needed therapies into clinical studies faster. And I’m pleased to share we’ve made a real impact.
LLS & BURLINGTON STORES SURPRISE PEDIATRIC CANCER SURVIVORS WITH ONE-OF-A-KIND OUTDOOR “PATIENT PARADES” AT SELECT STORE LOCATIONS NATIONWIDE
As part of Burlington’s annual in-store fundraising campaign, they’re hosting celebratory drive-by ‘parades’ for children battling cancer...